High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373793" target="_blank" >RIV/00216208:11130/17:10373793 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/17:10373793

Výsledek na webu

<a href="https://doi.org/10.1016/j.imlet.2017.05.005" target="_blank" >https://doi.org/10.1016/j.imlet.2017.05.005</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.imlet.2017.05.005" target="_blank" >10.1016/j.imlet.2017.05.005</a>

Jazyk výsledku

angličtina

Název v původním jazyce

High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy

Popis výsledku v původním jazyce

High hydrostatic pressure (HHP) can be used to generate dendritic cell (DC)-based active immunotherapy for prostate, lung and ovarian cancer. We showed here that HHP treatment of selected human cancer cell lines leads to a degradation of tumor antigens which depends on the magnitude of HHP applied and on the cancer cell line origin. Whereas prostate or ovarian cell lines displayed little protein antigen degradation with HHP treatment up to 300 MPa after 2 h, tumor antigens are hardly detected in lung cancer cell line after treatment with HHP 250 MPa at the same time. On the other hand, quick reduction of tumor antigen-coding mRNA was observed at HHP 200 MPa immediately after treatment in all cell lines tested. To optimize the DC -based active cellular therapy protocol for HHP-sensitive cell lines the immunogenicity of HHP-treated lung cancer cells at 150, 200 and 250 MPa was compared. Lung cancer cells treated with HHP 150 MPa display characteristics of immunogenic cell death, however cells are not efficiently phagocytosed by DC. Despite induction of the highest number of antigen-specific CD8(+) T cells, 150 MPa-treated lung cancer cells survive in high numbers. This excludes their use in DC vaccine manufacturing. HHP of 200 MPa treatment of lung cancer cells ensures the optimal ratio of efficient immunogenic killing and delivery of protein antigens in DC. These results represent an important pre-clinical data for generation of immunogenic killed lung cancer cells in ongoing NSCLC Phase I/II clinical trial using DC-based active cellular immunotherapy (DCVAC/LuCa).

Název v anglickém jazyce

High hydrostatic pressure affects antigenic pool in tumor cells: Implication for dendritic cell-based cancer immunotherapy

Popis výsledku anglicky

High hydrostatic pressure (HHP) can be used to generate dendritic cell (DC)-based active immunotherapy for prostate, lung and ovarian cancer. We showed here that HHP treatment of selected human cancer cell lines leads to a degradation of tumor antigens which depends on the magnitude of HHP applied and on the cancer cell line origin. Whereas prostate or ovarian cell lines displayed little protein antigen degradation with HHP treatment up to 300 MPa after 2 h, tumor antigens are hardly detected in lung cancer cell line after treatment with HHP 250 MPa at the same time. On the other hand, quick reduction of tumor antigen-coding mRNA was observed at HHP 200 MPa immediately after treatment in all cell lines tested. To optimize the DC -based active cellular therapy protocol for HHP-sensitive cell lines the immunogenicity of HHP-treated lung cancer cells at 150, 200 and 250 MPa was compared. Lung cancer cells treated with HHP 150 MPa display characteristics of immunogenic cell death, however cells are not efficiently phagocytosed by DC. Despite induction of the highest number of antigen-specific CD8(+) T cells, 150 MPa-treated lung cancer cells survive in high numbers. This excludes their use in DC vaccine manufacturing. HHP of 200 MPa treatment of lung cancer cells ensures the optimal ratio of efficient immunogenic killing and delivery of protein antigens in DC. These results represent an important pre-clinical data for generation of immunogenic killed lung cancer cells in ongoing NSCLC Phase I/II clinical trial using DC-based active cellular immunotherapy (DCVAC/LuCa).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Immunology Letters

ISSN

0165-2478

e-ISSN

—

Svazek periodika

187

Číslo periodika v rámci svazku

July

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

8

Strana od-do

27-34

Kód UT WoS článku

000403633100005

EID výsledku v databázi Scopus

2-s2.0-85019120416